Presage Biosciences is dedicated to improving the cancer drug development process so that patients can receive the most effective treatment possible.
Our proprietary technology platform allows for the rapid, reliable assessment of multiple cancer therapeutics directly in a tumor in its native microenvironment. This provides the first side-by-side comparison of multiple drugs and drug combinations within a single living tumor.
This patented technology heralds an innovative and elegant new approach to selecting optimal drug candidates and efficiently advancing cancer therapeutics to the market.
Presage was founded in 2008 based on technology invented at the Fred Hutchinson Cancer Research Center. Presage is a privately held company headquartered in Seattle that is led by a passionate and experienced management team.